EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss of $0.62, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss of $0.62, Revenues Beat

EyePoint Pharmaceuticals (EYPT) Reports Election of Goran Ando M.D. as Next Board Chairman

September 10, 2018 7:03 AM EDT

EyePoint Pharmaceuticals (NASDAQ: EYPT) today announced that the Companys Board of Directors has elected Göran Ando, M.D., as its next Chairman of the Board. As part of this transition, David J. Mazzo, Ph.D., will step-down as Non-Executive Chairman, but will remain on the Board and will continue to serve as Chair of the Compensation Committee.

We are pleased to have Dr. Ando serve as our Chairman of the Board as we continue our transition into a commercial-stage specialty pharmaceuticals company, said Nancy... More